Normal view MARC view ISBD view

Gupta, Smita

Immunotherapies in diabetes mellitus type 1. [electronic resource] - The Medical clinics of North America May 2012 - 621-34, xi p. digital

Publication Type: Journal Article; Review

ISSN: 1557-9859

Standard No.: 10.1016/j.mcna.2012.04.008 doi

Subjects--Topical Terms:
Abatacept
Antibodies, Monoclonal--therapeutic use
Antibodies, Monoclonal, Humanized--therapeutic use
Antibodies, Monoclonal, Murine-Derived--therapeutic use
Antilymphocyte Serum--therapeutic use
Azathioprine--therapeutic use
Basiliximab
Chaperonin 60--therapeutic use
Cyclosporine--therapeutic use
Daclizumab
Diabetes Mellitus, Type 1--immunology
Diet
Etanercept
Exenatide
Fatty Acids, Unsaturated--therapeutic use
Glutamate Decarboxylase--therapeutic use
Humans
Hypoglycemic Agents--immunology
Immunoconjugates--therapeutic use
Immunoglobulin G--therapeutic use
Immunosuppressive Agents--therapeutic use
Insulin--immunology
Interferon-alpha--therapeutic use
Interleukin 1 Receptor Antagonist Protein--therapeutic use
Islets of Langerhans Transplantation
Niacinamide--therapeutic use
Peptide Fragments--therapeutic use
Peptides--therapeutic use
Primary Prevention
Pyrazines--therapeutic use
Receptors, Tumor Necrosis Factor--therapeutic use
Recombinant Fusion Proteins--therapeutic use
Rituximab
Secondary Prevention
Sitagliptin Phosphate
Tertiary Prevention
Triazoles--therapeutic use
Venoms--therapeutic use
Vitamin D--therapeutic use
Vitamins--therapeutic use